Advanced

Bone Scan Index: A prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy

Kaboteh, Reza; Damber, Jan-Erik; Gjertsson, Peter; Höglund, Peter LU ; Lomsky, Milan; Ohlsson, Mattias LU and Edenbrandt, Lars LU (2013) In EJNMMI Research 3(1). p.1-6
Abstract

Background: The objective of this study was to explore the prognostic value of the Bone Scan Index (BSI) obtained at the time of diagnosis in a group of high-risk prostate cancer patients receiving primary hormonal therapy. Methods: This was a retrospective study based on 130 consecutive prostate cancer patients at high risk, based on clinical stage (T2c/T3/T4), Gleason score (8 to 10) and prostate-specific antigen (PSA) (> 20 ng/mL), who had undergone whole-body bone scans < 3 months after diagnosis and who received primary hormonal therapy. BSI was calculated using an automated method. Cox proportional-hazards regression models were used to investigate the association between clinical stage, Gleason score, PSA, BSI and survival.... (More)

Background: The objective of this study was to explore the prognostic value of the Bone Scan Index (BSI) obtained at the time of diagnosis in a group of high-risk prostate cancer patients receiving primary hormonal therapy. Methods: This was a retrospective study based on 130 consecutive prostate cancer patients at high risk, based on clinical stage (T2c/T3/T4), Gleason score (8 to 10) and prostate-specific antigen (PSA) (> 20 ng/mL), who had undergone whole-body bone scans < 3 months after diagnosis and who received primary hormonal therapy. BSI was calculated using an automated method. Cox proportional-hazards regression models were used to investigate the association between clinical stage, Gleason score, PSA, BSI and survival. Discrimination between prognostic models was assessed using the concordance index (C-index). Results: In a multivariate analysis, Gleason score (p = 0.01) and BSI (p < 0.001) were associated with survival, but clinical stage (p = 0.29) and PSA (p = 0.57) were not prognostic. The C-index increased from 0.66 to 0.71 when adding BSI to a model including clinical stage, Gleason score and PSA. The 5-year probability of survival was 55% for patients without metastases, 42% for patients with BSI < 1, 31% for patients with BSI = 1 to 5, and 0% for patients with BSI > 5. Conclusions: BSI can be used as a complement to PSA to risk-stratify high-risk prostate cancer patients at the time of diagnosis. This imaging biomarker, reflecting the extent of metastatic disease, can be of value both in clinical trials and in patient management when deciding on treatment.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Bone metastases, Image analysis, Prostate cancer, Radionuclide imaging
in
EJNMMI Research
volume
3
issue
1
pages
6 pages
publisher
BioMed Central
external identifiers
  • scopus:84875333209
  • wos:000209435800009
ISSN
2191-219X
DOI
10.1186/2191-219X-3-9
language
English
LU publication?
yes
id
69dba21a-c840-4804-99ef-87a948d8711a
date added to LUP
2017-05-16 16:32:45
date last changed
2018-01-16 13:26:26
@article{69dba21a-c840-4804-99ef-87a948d8711a,
  abstract     = {<p>Background: The objective of this study was to explore the prognostic value of the Bone Scan Index (BSI) obtained at the time of diagnosis in a group of high-risk prostate cancer patients receiving primary hormonal therapy. Methods: This was a retrospective study based on 130 consecutive prostate cancer patients at high risk, based on clinical stage (T2c/T3/T4), Gleason score (8 to 10) and prostate-specific antigen (PSA) (&gt; 20 ng/mL), who had undergone whole-body bone scans &lt; 3 months after diagnosis and who received primary hormonal therapy. BSI was calculated using an automated method. Cox proportional-hazards regression models were used to investigate the association between clinical stage, Gleason score, PSA, BSI and survival. Discrimination between prognostic models was assessed using the concordance index (C-index). Results: In a multivariate analysis, Gleason score (p = 0.01) and BSI (p &lt; 0.001) were associated with survival, but clinical stage (p = 0.29) and PSA (p = 0.57) were not prognostic. The C-index increased from 0.66 to 0.71 when adding BSI to a model including clinical stage, Gleason score and PSA. The 5-year probability of survival was 55% for patients without metastases, 42% for patients with BSI &lt; 1, 31% for patients with BSI = 1 to 5, and 0% for patients with BSI &gt; 5. Conclusions: BSI can be used as a complement to PSA to risk-stratify high-risk prostate cancer patients at the time of diagnosis. This imaging biomarker, reflecting the extent of metastatic disease, can be of value both in clinical trials and in patient management when deciding on treatment.</p>},
  author       = {Kaboteh, Reza and Damber, Jan-Erik and Gjertsson, Peter and Höglund, Peter and Lomsky, Milan and Ohlsson, Mattias and Edenbrandt, Lars},
  issn         = {2191-219X},
  keyword      = {Bone metastases,Image analysis,Prostate cancer,Radionuclide imaging},
  language     = {eng},
  number       = {1},
  pages        = {1--6},
  publisher    = {BioMed Central},
  series       = {EJNMMI Research},
  title        = {Bone Scan Index: A prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy},
  url          = {http://dx.doi.org/10.1186/2191-219X-3-9},
  volume       = {3},
  year         = {2013},
}